Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 11:35:09 2024-04-29 am EDT			5-day change	1st Jan Change
27.68 ^EUR	+1.73%		+1.10%	-1.39%

Apr. 29	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	MT
Apr. 26	FRESENIUS SE : Jefferies reiterates its Buy rating	ZD

Fresenius : 2023 ESG KPI Overview

March 21, 2024

We report on the effectiveness of our material nonfinancial topics by monitoring key performance indicators (KPI). This overview contains both audited and non-audited data. Audited KPIs are taken from the Annual Report. Additional non-audited KPIs are provided in this overview and marked accordingly.

This overview is currently only available in English.

Fresenius Group Annual Report 2023

Fresenius Group Non-financial Report 2023

1. Quality

1.1 Patients treated	2023	2022	2021	2020	2019
Fresenius Helios	25,772,029 24,868,792 22,567,138 20,189,521 20,962,664
thereof inpatient Helios Germany	1,131,581	1,079,776	1,048,946	1,044,959	1,206,654
thereof outpatient Helios Germany	4,334,425	4,423,482	4,390,553	4,101,716	4,354,527
thereof inpatient Helios Spain	1,153,240	1,093,858	982,204	927,414	845,560
thereof outpatient Helios Spain	19,147,918	18,266,776	16,140,388	14,110,390	14,550,491
Data 2022 and 2023 audited, data 2019 to 2021 non-audited

1.2 Healthcare facilities	2023	2022	2021	2020	2019
Fresenius Helios
Acute care clinics	145	145	146	141	134
thereof Germany	86	87	90	89	83
thereof Spain/Latin America	59	58	56	52	51
Other healthcare facilities or centers	>650	>650	>500	>500	>500
Number of beds in acute care:	37,709	38,045	38,129	37,387	35,668
in clinics Germany	29,410	29,786	29,955	29,451	28,380
in clinics Spain and Latin America	8,299	8,259	8,174	7,936	7,288
Number of beds unaudited data; Number of health care facilities and clinics reported in Group Management Report.

1.3 Quality Commitment	2023	2022	2021	2020	2019
Coverage by external quality management
standard	100%	100%	n.a.	n.a.	n.a.
thereof ISO 9001 coverage	97%	61%	n.a.	n.a.	n.a.
Internal standard or policy	100%	100%	n.a.	n.a.	n.a.
Regulatory requirement
(e.g. national law)	100%	100%	n.a.	n.a.	n.a.

Coverage within the business segments depends on the applicability of standards or policies; focus on operations and hospitals; data 2023 audited.

1.4 Quality Management in

Patient Care	2023	2022	2021	2020	2019
Fresenius Helios, Germany
Average length of stay (days)	5.7	5.8	5.7	5.7	5.8
G-IQI targets achieved 1	88.7%	87.0%	86.8%	88.4%	87.7%

G-IQI-target 2023 audited with reasonable assurance, data 2019 to 2022 with limited assurance. Other data non-audited.

Page 1 / 12

March 2024

1.4 Quality Management in

Patient Care (contd.)	2023	2022	2021	2020	2019
Peer Reviews 1	22	9	7	8	60
CIRS reports (Critical Incident Reporting
System)1	955	767	547	n.a.	n.a.
Allegations of treatment errors (justified
or unjustified)2	840	828	768	958	1,082
Average treatment errors per 1,000
patients2	0.7	0.8	0.8	0.9	0.9
Patient service monitor3
Patient interviews (acute care)	719,025	739,660	713,382	n.a.	n.a.
% of patients treated	64.0	70.0	70.0	n.a.	n.a.
Patient satisfaction in %	96	96.0	96.0	n.a.	n.a.
Fresenius Helios, Spain
Net Promoter Score, Spain1	60.1	56.3	49.9	54.1	54.6
Total Reports (NPS), Spain1	818,485	652,269	534,930	361,800	426,061
Peer Reviews1	1	4	4	2	8
Patient Safety Incidents1	11,487	11,299	8,508	4,897	4,350

Data 2021 to 2023 audited
Average allegation of treatment error (justified or unjustified) per 1,000 patients; incl. all specialties and all stages of treatment, from patient information, diagnostics, surgery, and therapy and to aftercare. Data non-audited.
Data 2023 audited
1.5 Quality Management in

Production	2023	2022	2021	2020	2019
Fresenius Kabi
Audit and inspection score1	1.9	2.3	1.9	1.3	1.5
Internal audits	58	45	58	42	60
External audits and inspections	111	87	94	59	64
Compliance rates for quality-related
reporting
Side effects: individual case reports
reported in time (globally)	99.9	99.3	99.6	99.9	99.9
Benefit-risk-ratio: in time transmission of
periodic safety reports (globally)	99.1	100	98.8	99.6	99.1
Internal in time transmission of vigilance
data	100	100	100	100	100.0
Communication of new side effects	1	1	n.a.	n.a.	n.a.

1For the calculation of the audit and inspection score, Fresenius Kabi takes into account all information on findings from audits and inspections received by the company before December 31 of the reporting year. Data audited.

Page 2 / 12

March 2024

2. Innovation

2.1 R&D	2023	2022	2021	2020	2019
R&D expenses, € in millions1	607	631	574	560	522
as % of product revenue	7.6	8.0	8.1	8.2	7.7

1 for special items, see the "Research and Development" section in the Annual Reports 2022 and 2023; data audited.

2.2 Clinical Studies	2023	2022	2021	2020	2019
Clinical studies, total	1,873	1,651	1,747	1,698	n.a.
Public funding (Spain, in EUR million)	~6	~9	n.a.	n.a.	n.a.
Data 2023 audited

3. Digitalization

3.1 Digitalization rate	2023	2022	2021	2020	2019
Fresenius Helios, Spain
Goal: Usage rate of digital care
management of 80% by 2024
Arrangements for medical tests,
appointments or surgeries, in %	74.1	n.a.	n.a.	n.a.	n.a.
Signing of consent forms, in %	51.6	n.a.	n.a.
Surgical checklists, in %	66.0	n.a.	n.a.	n.a.	n.a.
Data audited

4. Cybersecurity

4.1 Cyberincidents	2023	2022	2021	2020	2019
Serious incidents (Group perspective)	0	0	0	n.a.	n.a.
thereof patients	-	-	-	n.a.	n.a.
Data audited

5. Employees

5.1 Headcount, FTE	2023	2022	2021	2020	2019
Headcount, total	193,865	188,876	185,827	178,140	165,834
Fresenius Kabi	43,269	42,063	41,397	40,519	39,627
Fresenius Helios	129,439	125,700	123,484	116,952	106,377
Fresenius Vamed	20,265	20,184	19,721	19,414	18,592
Corporate / Other	892	929	1,225	1,255	1,238
FTE, total	166,834	161,808	158,102	152,461	142,245
Fresenius Kabi	41,381	40,286	39,579	39,032	38,264
Fresenius Helios	108,208	104,509	101,652	96,899	88,057
Fresenius Vamed	16,430	16,182	15,730	15,364	14,770
Corporate / Other	815	831	1,141	1,166	1,154
Temporary staff (as of December)	2,756	3,749	n.a.	n.a.	n.a.
Europe	1,326	1,814	n.a.	n.a.	n.a.
Rest of the World	1,430	1,479	n.a.	n.a.	n.a.

Temporary staff excl. Fresenius Helios; data audited

Page 3 / 12

March 2024

5.2 Recruiting	2023	2022	2021	2020	2019
New hires, %1, 2	19.1	19.7	n.a.	n.a.	n.a.
thereof females (headcount), Group	20,092	n.a.	n.a.	n.a.	n.a.
Fresenius Kabi, in %	17.0	16.9	17.1	13.5	17.1
thereof females (headcount)	n.a.	n.a.	n.a.	n.a.	n.a.
Fresenius Helios, in %	19.3	20.0	22.9	18.0	16.9
thereof females (headcount)	17,301	n.a.	n.a.	n.a.	n.a.
Fresenius Vamed, in %	22.0	23.6	18.4	18.4	17.8
thereof females (headcount)	2,724	n.a.	n.a.	n.a.	n.a.
Corporate / Other, in %	16.0	14.5	11.0	6.1	11.2
thereof females (headcount)	67	n.a.	n.a.	n.a.	n.a.
New hires, in % 4 by region
Europe	18.5	19.6	n.a.	n.a.	n.a.
Germany	15.4	15.6	n.a.	n.a.	n.a.
Europe excl. Germany	23.1	25.6	n.a.	n.a.	n.a.
North America	24.6	36.7	n.a.	n.a.	n.a.
Asia-Pacific	12.9	17.0	n.a.	n.a.	n.a.
Latin America	25.2	18.2	n.a.	n.a.	n.a.
Africa	11.3	15.7	n.a.	n.a.	n.a.

Calculated as the number of external hires in a business segment within the reporting period, relative to the number of employees at year-end. Segment KPI audited. Inter-segment hires excluded for Corporate/Other; Fresenius Kabi does not yet report the gender-specific data by region
The data contains the hospitals in Latin America as of 2020. Data for 2022 and 2023 contains the Spanish entities of Eugin Group.

5.3 Staff loyalty	2023	2022	2021	2020	2019
Total turnover, %1	29.9	32.8	n.a.	n.a.	n.a.
dismissal, %2	1.9	1.4	n.a.	n.a.	n.a.
thereof within probation period 5	0.9	0.9	n.a.	n.a.	n.a.
Voluntary turnover, %2, 3	10.4	11.1	10.1	9.8	11.0
Fresenius Kabi	10.2	11.4	11.3	7.1	9.2
Fresenius Helios	10.6	11.1	10.1	90.0	8.6
Fresenius Vamed	9.5	10.7	9.3	7.8	7.6
Corporate / Other	6.1	14.2	3.5	1.7	3.5
Voluntary turnover, in % by region4
Europe	10.0	10.7	n.a.	n.a.	n.a.
Germany	7.8	8.4	n.a.	n.a.	n.a.
Europe excl. Germany	13.5	14.3	n.a.	n.a.	n.a.
North America	14.4	18.4	n.a.	n.a.	n.a.
Asia-Pacific	12.7	14.9	n.a.	n.a.	n.a.
Latin America	11.3	11.1	n.a.	n.a.	n.a.
Africa	5.0	7.1	n.a.	n.a.	n.a.

Total turnover includes contracts which ended in the reporting year; only voluntary turnover of Fresenius Kabi outside Germany. Voluntary turnover by Group and business segment audited.
Data contains hospitals in Latin America as of 2020. Data for 2022 and 2023 incl. Spanish entities of Eugin Group. Dismissal data non-audited
Number of employees who left the organization voluntarily in relation to the number of employees at the end of the year. Data audited
non-audited

Page 4 / 12

March 2024

5.4 Employee retention	2023	2022	2021	2020	2019
Average length of service, years 1	8.8	8.8	8.8	8.9	9.2
Fresenius Kabi	7.9	7.9	7.9	7.9	8.6
Fresenius Helios	9.1	9.2	9.3	9.4	9.9
Fresenius Vamed	8.6	8.5	7.8	7.7	6.9
Corporate / Other	7.7	7.8	7.8	7.5	7.3
Average length of service (years), by region
Europe	9.3	9.3	7.8	n.a.	n.a.
thereof Germany	9.9	10.1	n.a.	n.a.	n.a.
thereof Rest of Europe	8.3	8.3	n.a.	n.a.	n.a.
North America	6.5	6.5	n.a.	n.a.	n.a.
Asia-Pacific	7.8	7.2	n.a.	n.a.	n.a.
Latin America	6.4	6.5	n.a.	n.a.	n.a.
Africa	6.7	7.7	n.a.	n.a.	n.a.

1 Group and business segment data audited

5.5 Employee participation	2023	2022	2021	2020	2019
Collective bargaining agreements 1
Coverage in Europe	84%	83%	83%	77%	71%
Coverage outside Europe	31%	34%	15%	n.a.	n.a.
Global coverage	74%	80%	80%	n.a.	n.a.

1 2023 coverage 100% global employees. 2021 to 2022 based on about 91% of Fresenius Group total employees; data 2020 and 2019 incl. FME.

5.6 Working Models	2023	2022	2021	2020	2019
Full-time employees 1
share of men	80%	80%	82%	82%	n.a.
share of women	60%	60%	58%	58%	n.a.
Employees working full-time1	66%	66%	65%	65%	n.a.
thereof male	35%	32%	36%	36%	n.a.
thereof female	65%	68%	64%	64%	n.a.
Part-time employees 1	34%	34%	35%	35%
share of men	20%	20%	18%	18%	n.a.
share of women	40%	40%	42%	42%	n.a.
Employees working part-time1	34%	34%	35%	36%	n.a.
thereof male	17%	17%	15%	15%	n.a.
thereof female	83%	83%	85%	85%	n.a.
Parental leave, %2	4%	5%	5%	5%	n.a.
thereof male, %	19%	19%	20%	18%	n.a.
thereof female, %	81%	81%	80%	82%	n.a.
Parental leave, % by region	7%	6%
Europe	n.a.	n.a.	n.a.
Germany	5%	6%	6%	6%	n.a.

2022: Scope of 85% of employees globally. 2021 German entities and business segment Fresenius Helios (excl. Fertility business); 2020 only Germany incl.
FME
2022: Scope of around 50% of global employees, incl. FME

Working Model KPI not audited

Page 5 / 12

March 2024

5.7 Employee engagement	2023		2022	2021	2020	2019
Employee engagement index1	4.13		3.9	n.a.	n.a.	n.a.
Fresenius Kabi	4.7		4.4	n.a.	n.a.	n.a.
Fresenius Helios	3.9		3.7	n.a.	n.a.	n.a.
Fresenius Vamed	4.1	n.a.		n.a.	n.a.	n.a.
Corporate/Other	4.0		3.7	n.a.	n.a.	n.a.
Participation rate	44%		56%	n.a.	n.a.	n.a.

1 Audited with reasonable assurance, as stated in the independent practitioner´s report. In 2022, audit performed with limited assurance.

5.8 Labor Cost	2023	2022	2021	2020	2019
Personnel expenses1
in total, € million	9,930	9,439	15,610	15,128	14,355
thereof wages and salaries	8,144	7,715	12,679	12,357	11,651
per average employee (€ thou.)	51.8	50.1	49.8	49.5	49.5
in % of sales	44.5	43.8	41.6	41.7	40.5
Average employee compensation, in € 2	42,009	40,847	68,230	69,367	70,257
Ratio CEO 3 /Avg. Employee compensation,
%	41.35	104.48	91.09	92.02	139.38

Data 2019 to 2021 incl. Fresenius Medical Care
Calculated as total wages and salaries divided by total headcount
higher impact in 2022 due to change in board structure; consideration of both CEO salaries: unaudited

6. Diversity, Equity & Inclusion

6.1 Age structure	2023	2022	2021	2020	2019
Age structure (Headcount)
Below 30 years, in %	21	20	20	19	19
Between 30 and 50 years, in %	52	53	53	55	55
Above 50 years, in %	27	27	27	26	26
Average age (Headcount), years 2	41.3	41.4	41.3	41.7	41.0
Fresenius Kabi	39.5	39.5	39.2	39.9	38.7
Fresenius Helios	41.5	41.6	41.5	41.6	42.0
Fresenius Vamed	44.3	44.1	44.3	44.0	41.2
Corporate / Other	39.0	38.9	39.7	39.3	39.1

Data audited; data 2019 to 2020 incl. Fresenius Medical Care

6.2 Global DEI indicators	2023	2022	2021	2020	2019
Employees with disability 1
in Germany	4,668	4,614	5,051	5,027	4,724
in % of employees	5.1%	5.0%	5.1%	5.7%	5.7%
in Europe	5,417	5,214	5,531	5,452	5,171
in % of employees	3.8%	3.7%	4.0%	4.1%	4.1%
Nationalities	>150	>145	>140	>150	>150

1 Scope 2023: Total staff except Kabi outisde Germany. Unitl 2022 total staff Germany; Europe: clinics of Fresenius Helios in Spain as of 2019; European entities of Fresenius Vamed as of 2022, Fresenius Kabi only Germany; data 2021 to 2023 audited

Page 6 / 12

March 2024

6.3 Headcount by gender	2023	2022	2021	2020	2019
Headcount, female employees	132,377	128,795	126,735	120,927	112,021
in %	68	68	68	68	68
Fresenius Kabi	52	51	51	50	50
Fresenius Helios	75	75	75	75	75
Fresenius Vamed	63	63	62	62	63
Corporate / Other	47	46	40	38	39
Headcount, by region and gender
Europe	155,883	152,510	151,025	145,573	131,464
thereof Germany	93,095	91,093	90,655	88,879	83,378
female	72%	73%	n.a.	n.a.	n.a.
male	28%	27%	n.a.	n.a.	n.a.
other	0%	0%	n.a.	n.a.	n.a.
undisclosed	0%	n.a.	n.a.	n.a.	n.a.
thereof Europe excl. Germany	62,788	61,417	60,370	56,694	54,110
female	68%	68%	n.a.	n.a.	n.a.
male	32%	32%	n.a.	n.a.	n.a.
other	0%	0%	n.a.	n.a.	n.a.
undisclosed	0%	n.a.	n.a.	n.a.	n.a.
North America	5,410	11,306	10,508	8,809	8,321
female	43	43%	n.a.	n.a.	n.a.
male	57%	57%	n.a.	n.a.	n.a.
other	0%	0%	n.a.	n.a.	n.a.
undisclosed	0%	n.a.	n.a.	n.a.	n.a.
Asia-Pacific	9,646	10,029	10,744	11,035	11,050
female	44%	44%	n.a.	n.a.	n.a.
male	56%	56%	n.a.	n.a.	n.a.
other	0%	0%	n.a.	n.a.	n.a.
undisclosed	0%	n.a.	n.a.	n.a.	n.a.
Latin America	21,762	13,913	12,557	11,725	7,952
female	65%	64%	n.a.	n.a.	n.a.
male	35%	36%	n.a.	n.a.	n.a.
other	0%	0%
undisclosed	0%	n.a.
Africa	1,164	1,118	993	998	1,023
female	60%	58%	n.a.	n.a.	n.a.
male	40%	42%	n.a.	n.a.	n.a.
other	0%	0%	n.a.	n.a.	n.a.
undisclosed	0%	n.a.	n.a.	n.a.	n.a.
Data non-audited

6.4 Women in Leadership	2023	2022	2021	2020	2019
Share of women in management:	501	522	n.a.	n.a.	n.a.
participating in LTIP	27%	28%	n.a.	n.a.	n.a.

Data audited

Page 7 / 12

March 2024

6.4 Women in Leadership

Share of women in management: 1st level below Management Board 2nd level below Management Board

2023	2022	2021	2020	2019
30.0%
n.a.	n.a.	n.a.	n.a.
24.1%	n.a.	n.a.	n.a.	n.a.

2023 data audited

6.5 Board Diversity	2023	2022	2021	2020	2019
Management Board
Share of women	20%	17%	14%	14%	14%
members between 30 and 50 years	40%	17%	14%	14%	14%
members over 50 years	60%	83%	86%	86%	86%
Average age	51.6	53.2	57.1	n.a.	n.a.
Non-Germans	20%	33%	43%	57%	57%
Average tenure (years)	0.6	5.2	7.9	8.0	8.9
Supervisory Board 1
Share of women	17%	42%	42%	42%	33%
members between 30 and 50 years	17%	17%	17%	17%	8%
members over 50 years	83%	83%	83%	83%	92%
Average age	61.6	60.7	60.7	n.a.	n.a.
Non-Germans	33%	17%	17%	25%	25%
Average tenure (years)	5.8	5.3	6.0	6.5	6.6

1 Applies to total board

7. Occupational health & safety

7.1 LTIFR	2023	2022	2021	2020	2019
Fresenius Kabi	2.8	2.9	2.4	2.3	2.6
Fresenius Helios (Spain)	14.6	16.2	n.a.	n.a.	n.a.
Fresenius Vamed	12.5	16.7	n.a.	n.a.	n.a.

LTIFR: Number of work-related accidents resulting in at least one day of absence from work in relation to 1,000,000 working hours. In 2023, Fresenius Vamed adjusted the scope of reporting. Data audited

7.2 Work-related fatal accidents	2023	2022	2021	2020	2019
Group (own employees)	0	0	5	n.a.	n.a.
Temporary staff	0	0	0	n.a.	n.a.
Third-party fatalities	1	0	2	n.a.	n.a.

2021 data without the business segment Fresenius Vamed; temporary staff recording only in the business segment Fresenius Kabi; Third-party fatalities only recorded in the business segments Fresenius Kabi and Helios Germany; incidents with official

investigation. Data audited

7.3 OHS Training	2023	2022	2021	2020	2019
Fresenius Helios Spain
Training sessions	>30,000	n.a.	n.a.	n.a.	n.a.
Participants	~16,000	n.a.	n.a.	n.a.	n.a.

Data audited

Page 8 / 12

March 2024

8. Compliance & Integrity

8.1 Compliance reports	2023	2022	2021	2020	2019
Reports, total	806	375	2,119	1,729	n.a.
thereof classified as no relevant
compliance reports	262	n.a.	n.a.	n.a.	n.a.
Business Integrity	51	88	105	110	n.a.
Data protection	25	26	659	368	n.a.
HR/Workplace	274	155	1,040	999	n.a.
Misuse of company assets	225	35	n.a.	n.a.	n.a.
Environmental Health and Safety	34	23	n.a.	n.a.	n.a.
Accounting, auditing and financial
reporting	3	8	n.a.	n.a.	n.a.
Human Rights	47	n.a.	n.a.	n.a.	n.a.
Other	147	40	n.a.	n.a.	n.a.

Data 2020 and 2021 incl. Fresenius Medical Care; Human rights was not reported separately in 2022.

8.3 Tax compliance	2023	2022	2021	2020	2019
Effective tax rate by region 1
Europe	-695.2%	30.8%	24.2%	25.5%	23.9%
North America	18.4%	21.2%	21.1%	22.2%	20.1%
Asia-Pacific	21.1%	16.8%	23.4%	18.2%	23.6%
Latin America	26.5%	32.9%	26.4%	-27.5%	57.1%
Africa	-24.5%	-11.7%	28.0%	-193.8%	63.6%
Group	66.7%	24.8%	22.8%	24.2%	22.6%

Effective tax rate by country 2
USA	18.1%	21.1%	n.a.	n.a.	n.a.
Germany	303.6%	56.3%	n.a.	n.a.	n.a.
Spain	27.8%	19.5%	n.a.	n.a.	n.a.
China	15.7%	20,5% 3	n.a.	n.a.	n.a.

Special items in fiscal year 2023 are explained on page 299 of the Notes. Data not covered in Notes are unaudited data.
The four countries represent around 70% of Group sales
adjusted tax rate

8.4 Human rights	2023	2022	2021	2020	2019
Risk assessments	939	n.a.	n.a.	n.a.	n.a.
Recognized risks	11	n.a.	n.a.	n.a.	n.a.
Training sessions	61	n.a.	n.a.	n.a.	n.a.
Suppliers	58,000	n.a.	n.a.	n.a.	n.a.

Data audited

Page 9 / 12

March 2024

9. Environment

9.1 Environmental

Commitment1	2023	2022	2021	2020	2019
Coverage by external environmental
management standard
thereof ISO 14001 coverage	55%	46%	n.a.	n.a.	n.a.
thereof ISO 50001 coverage	82%	70%
Internal standard or policy	100%	100%	n.a.	n.a.	n.a.
Regulatory requirement
(e.g. national law)	100%	100%	n.a.	n.a.	n.a.

1 Scope applies to the entities for which environmental data is consolidated; focus on operations and hospitals; deviations due to scope adjustements

9.2 Water withdrawal	2023	2022	2021	2020	2019
Group 1, in million m3	15.1	15.6	15.0	14.6	14.0
Market segment healthcare products	9.9	10.4	10.1	9.7	9.5
Market segment healthcare facilities	5.2	5.2	4.9	4.9	4.5
Group by source, in million m3
Surface water	0.7	0.7	0.7	0.7	0.7
Groundwater	4.1	4.4	4.0	3.9	4.3
Seawater	0.0	0.0	0.0	0.0	0.0
Produced water	0.0	0.0	0.0	0.0	0.0
Third -party water (municipal supply)	10.3	10.6	10.3	10.0	52.2
Fresenius Group1 relative water
withdrawal
Water withdrawal / € 1 million3	671	718	797	1,550	16,093
Water withdrawal / FTE3	92.0	98.1	97.0	203.3	217.5
Water withdrawal (m3) per square meter 2
(hospital business)	0.76	0.80	n.a.	n.a.	n.a.
Water withdrawal (m3) per
hospital bed 2	108	110	106	109	106

Newly acquired companies are included in the second year of consolidation, at the latest. If data of the business segments is not available in time, it is extrapolated on the basis of existing data. An adjustment will be made in the next report. Prior-year information was adjusted to conform to the current year's presentation. Due to rounding, individual numbers and percentages presented in this report may not precisely reflect the absolute figures. Fresenius Medical Care water figures include the water withdrawal of its production sites and in-center treatments at its dialysis clinics. Data of Fresenius Helios's fertility services division include in 2022 and 2023 only the Spanish entities.
Data applies to business segment Fresenius Helios; excluding fertility services

Data 2019 to 2020 incl. Fresenius Medical Care

9.3 Water consumption	2023	2022	2021	2020	2019
in million m3
Water withdrawal1	9.9	10.4	10.1	9.7	n.a.
Water discharge	8.0	8.3	7.9	7.7	n.a.
Water consumption	1.9	2.1	2.2	2.0	n.a.

1 Data applies to market segment healthcare products; unaudited

Page 10 / 12

March 2024

Attachments

Original Link
Original Document
Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 22 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 April 2024 21:31:54 UTC.

Latest news about Fresenius SE & Co. KGaA

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
FRESENIUS SE : Jefferies reiterates its Buy rating	Apr. 26	ZD
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
FRESENIUS SE : Warburg Research reiterates its Buy rating	Apr. 24	ZD
FRESENIUS SE : Goldman Sachs sticks Neutral	Apr. 23	ZD
Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA.	Apr. 22	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
FRESENIUS SE : Receives a Buy rating from Jefferies	Apr. 22	ZD
Barclays reads 'Overweight' for Fresenius SE - Target 35 Euro	Apr. 22	DP
FRESENIUS SE : Barclays reiterates its Buy rating	Apr. 22	ZD
FRESENIUS SE : Berenberg keeps its Buy rating	Apr. 22	ZD
Positive trend of FMC and Fresenius continues	Apr. 22	DP
FRESENIUS SE : Gets a Neutral rating from JP Morgan	Apr. 18	ZD
Lauterbach wants to press ahead with hospital reform despite differences	Apr. 17	DP
State report warns of risks in hospital reform	Apr. 17	DP
FRESENIUS SE : Deutsche Bank maintains a Buy rating	Apr. 17	ZD
Warnings against cutbacks in hospital reform	Apr. 17	DP
Federal and state governments to discuss hospital reform again	Apr. 17	DP
FRESENIUS SE : Gets a Buy rating from Deutsche Bank	Apr. 16	ZD
STOXX 600 nears six-week low on geopolitical jitters; Ericsson shines	Apr. 16	RE
Fresenius at a two-month high - Tyenne launch and fantasy figures	Apr. 16	DP
Fresenius at two-month high - Tyenne launch a milestone	Apr. 16	DP
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Cannabis law and clinic atlas in the Bundesrat	Mar. 22	DP

Chart Fresenius SE & Co. KGaA

Duration

Period

More charts

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-05-07 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.68 EUR

Average target price

36.22 EUR

Spread / Average Target

+30.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-1.39%	16.7B
CVS HEALTH CORPORATION	-14.58%	85.02B
HCA HEALTHCARE, INC.	+15.05%	82.37B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.49%	29.29B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.17%	17.21B
PURE HEALTH HOLDING	-31.58%	11.8B
FRESENIUS MEDICAL CARE AG	+1.82%	12.15B
DAVITA INC.	+31.86%	12.12B
EUROFINS SCIENTIFIC SE	-0.47%	12.13B
REDE D'OR SÃO LUIZ S.A.	-8.00%	11.67B

Other Healthcare Facilities & Services